Divergent pathways regulate ligand-independent activation of ER alpha in SK-N-BE neuroblastoma and COS-1 renal carcinoma cells.
The alpha-estrogen receptor (ER alpha) transcriptional activity can be regulated either by binding to the cognate ligand or by intracellular signaling pathways responsive to a variety of factors acting through cell membrane receptors. Studies carried out in HeLa and COS-1 cells demonstrated that the cross-coupling between estrogen and growth factor receptors is mediated by p21ras and requires phosphorylation of a specific serine residue (Ser 118 in the human ER alpha and Ser 122 in mouse ER alpha) located in the ER alpha N-terminal activation function 1 (AF-1). Likewise, in the SK-N-BE neuroblastoma cell line p21ras is involved in the cross-coupling between insulin and ER alpha receptors. However, in this cell line Ser 122 is not necessary for insulin-dependent activation of unliganded ER alpha. In addition, after insulin activation, the electrophoretic mobility associated to serine hyperphosphorylation of ER alpha in SK-N-BE and in COS-1 cells is different. Our study rules out the possibility of tyrosine phosphorylation in unliganded ER alpha activation by means of transactivation studies of ER alpha tyrosine mutants and analysis of Tyr phosphorylation immunoreactivity. The two cofactors for steroid receptors RIP 140 and SRC-1 do not seem to be specifically involved in the insulin-induced ER alpha transactivation. The present study demonstrates the possibility of an alternative, cell-specific pathway of cross-coupling between intracellular and membrane receptors, which might be of importance for the understanding of the physiological significance of this mode of activation in the nervous system.
Patrone
C
C
Centre Molecular Pharmaceology Laboratory, University of Milan, Italy.
Gianazza
E
E
Santagati
S
S
Agrati
P
P
Maggi
A
A
D000818:Animals; D002292:Carcinoma, Renal Cell / Q000473:pathology*; D047628:Estrogen Receptor alpha; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D006367:HeLa Cells; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000473:pathology*; D008024:Ligands; D051379:Mice; D009363:Neoplasm Proteins / Q000378:metabolism*; D009447:Neuroblastoma / Q000473:pathology*; D010766:Phosphorylation; D010768:Phosphoserine / Q000737:chemistry; D011499:Protein Processing, Post-Translational; D016283:Proto-Oncogene Proteins p21(ras) / Q000502:physiology*; D017526:Receptor, IGF Type 1 / Q000187:drug effects / Q000502:physiology*; D011972:Receptor, Insulin / Q000187:drug effects / Q000502:physiology*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology*; D015533:Transcriptional Activation / Q000502:physiology*; D014162:Transfection; D014407:Tumor Cells, Cultured
D047628:Estrogen Receptor alpha; D007328:Insulin; D008024:Ligands; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D011993:Recombinant Fusion Proteins; D010768:Phosphoserine; D017526:Receptor, IGF Type 1; D011972:Receptor, Insulin; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)